Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIG-012
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
RIG-012 (also known as RIG012) is a potent, small-molecule antagonist of retinoic acid-inducible gene I (RIG-I, also known as DDX58), a cytosolic pattern recognition receptor that acts as an RNA sensor in the innate immune system. Discovered by researchers at Yale University, RIG-012 inhibits RIG-I ATPase activity with an IC50 of 0.71 μM, thereby blocking downstream RIG-I signaling and suppressing the production of type I interferons (such as IFN-β) and interferon-stimulated genes (such as hRsad2/viperin). It is primarily utilized as a research-use-only laboratory tool to study innate immunity, viral sensing, and inflammatory pathways, and has been investigated in preclinical models of ovarian cancer and pneumonia.
- Other names
- 4-(benzyloxy)-3,3-diethyl-2H-benzo[g]indole-2,5(3H)-dioneRIG 012RIG012RIG-012
02
Targets
DDX58 (Retinoic acid-inducible gene I protein)
Beyond the preview
Go deeper on RIG-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIG-012.